Overview
- Provides a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans
- Addresses statistics and epidemiology of lung cancer, along with the incidence of lung cancer in non-smokers
- Evaluates the state of current therapies–immune, targeted therapies against EGFR TKIs, KRAS, ALK and the associated challenges, especially resistance mechanisms
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 890)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.Â
Editors and Affiliations
About the editors
Aamir Ahmad, PhD, is a Scientist at the Wayne State University School of Medicine Department of Pathology and the Karmanos Cancer Institute, with over 100 published scientific articles in peer-reviewed journals and many book chapters. He has been a member of leading cancer organizations such as American Association for Cancer Research (AACR, Philadelphia, USA) and International Union against Cancer (UICC, Geneva, Switzerland). In addition to serving as a reviewer for a number of peer-reviewed scientific journals, he is currently a Section Editor for the journal PLoS ONE responsible for policy drafts for the journal and identification and management of special issues. In addition to the current volume, Dr. Ahmad has worked with Springer to edit two more volumes, Breast Cancer Metastasis and Drug Resistance and Lung Cancer and Personalized Medicine: Current Knowledge and Therapies.
Shirish M. Gadgeel is a Professor in the Department of Oncology at Karmanos Cancer Institute/Wayne State University in Detroit. He is also the co-leader of the Molecular Therapeutics Program of Karmanos Cancer Institute and the Leader of the Multidisciplinary Thoracic Oncology team. He is
a member of several professional societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He currently serves on the Editorial Board of the journals Cancer and Clinical Lung Cancer. Dr. Gadgeel has been and is a Principal Investigator of several trials focused on the treatment of Lung Cancer. He has over 80 peer reviewed publications. ÂBibliographic Information
Book Title: Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Editors: Aamir Ahmad, Shirish M. Gadgeel
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-319-24932-2
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2016
Hardcover ISBN: 978-3-319-24931-5Published: 18 January 2016
Softcover ISBN: 978-3-319-79702-1Published: 30 March 2018
eBook ISBN: 978-3-319-24932-2Published: 24 December 2015
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: X, 231
Number of Illustrations: 1 b/w illustrations, 21 illustrations in colour
Topics: Cancer Research